IRCT20200105046010N34招募中未知
In- Vivo Bioequivalence study of Trientine hard capsules 250 mg with brand drug (CYPRINE® 250 mg Merck & Co., Germany) in Iranian healthy volunteers.
ano Pajhoohan Pardis Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index(18-28)
- •Informed consent
- •Age(18-60)
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
尚未招募
1 期
Bioequivalence of TrienorHealthy volunteersHealthy VolunteersRPCEC00000265Center for Pharmaceutical Research and Development, Havana, Cuba.72
尚未招募
Unknown
Investigating the in vivo bioequivalence of Tetrabenazine 25 mgIn the present study, the products will be administered to healthy volunteers..IRCT20210519051345N29Tabriz University of Medical Sciences24
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of methylprednisolone aceponate fatty ointment applied to the skin in healthy male and female volunteers.ACTRN12620000160932Zenith Technology Corporation Limited95
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of betamethsone ointment applied to the skin in healthy male and female volunteers.Betamethasone ointment is indicated for the topical treatment of eczema and psoriasis in children and adults.Skin - Dermatological conditionsACTRN12624000107527Zenith Technology Corporation Limited90
已完成
1 期
Pivotal in vivo bioequivalence study comparing two formulations of 21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone fatty ointment applied to the skin in healthy male and female volunteers.21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone fatty ointment is indicated for the short term treatment of the milder form of eczema, dermatitis and other steroid responsive skin conditionsSkin - Dermatological conditionsACTRN12623000571673Zenith Technology Corporation Limited90